Federal RuleAug 21
62
DOL Rewrites Disability Rules for 'Merit-Based Opportunity' Push
RuleLabor DepartmentFederal Contract Compliance Programs OfficeSignificant Wallet
119-hr-3520119th CongressWALLET
STAND Against Emerging Opioids Act
Sponsored By: Representative Panetta, Jimmy [D-CA-19]
Introduced
Summary
Schedules tianeptine as a Schedule III controlled substance. This bill would add tianeptine, including its analogues, salts, isomers, and salts of isomers, to Schedule III of the Controlled Substances Act. The scheduling would take effect 90 days after enactment.
Personalized for You
How does this bill affect your finances?
Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
New rules for tianeptine makers and sellers
If enacted, this bill would add tianeptine to Schedule III of the Controlled Substances Act. That includes its analogues, salts, and isomers. Makers, distributors, importers, prescribers, pharmacies, and retailers would need federal registration, records, and security. Unauthorized possession or sales could bring criminal penalties under Schedule III rules. This would take effect 90 days after enactment.
Sponsors & CoSponsors
Sponsor
Panetta, Jimmy [D-CA-19]
CA • D
Cosponsors
Rep. Pfluger, August [R-TX-11]
TX • R
Sponsored 5/20/2025
Rep. Kustoff, David [R-TN-8]
TN • R
Sponsored 6/12/2025
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov